🔍
Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence
JP
/
EN
Ethics · Regulation · Technology — Pharma Practice Notes
Regulation
Drug Harm History
10 chapters
Drug Harm History
#1
Elixir Sulfanilamide — The Starting Point of Modern Drug Regulation
#2
Thalidomide 1957–1962 / Worldwide — The Disaster That Built Modern Drug Regulation
#3
DES (Diethylstilbestrol) — A Drug Disaster Across Generations
#4
The SMON Incident — Birth of Japan's Post-Marketing Surveillance
#5
HIV-Tainted Blood Products in Japan — Systemic Non-Action and Its Aftermath
#6
The Drug-induced Hepatitis C Incident — Records Held but Not Used
#7
Creutzfeldt–Jakob Disease from Cadaveric Dura Mater
#8
Iressa (Gefitinib) — A "Miracle Drug" and Interstitial Pneumonia
#9
Vioxx (Rofecoxib) — The Ethics of Data Disclosure
#10
The Opioid Crisis — A Drug Disaster Not Yet Over
Ethics
8 chapters
Ethics
#1
Pharmaceutical Corporate Ethics — Holding the Tension Between Profit and Medicine
#2
From Nuremberg to Helsinki — The Events and Documents That Built Bioethics
#3
Medical Ethics — Four Principles and the Three at the Bedside
#4
If My Wife Were the Patient — Reading Patient Rights as a Stakeholder
#5
Personal Professional Ethics — When Rules and Judgment Diverge
#6
What is Ethics, in the First Place? — The "wrong-coffee" incident at Cafe Socrates
#7
Research Ethics: History and Present — How Participant Protection Was Institutionalized
#8
Publication Ethics: History and Present — The Conscience Mechanism Science Built for Itself
Compliance
6 chapters
Compliance
#1
Starting from "Life-Related Industry" — Reading the Walls Between Us and Patients
#2
Social Trust — The Condition for This Industry to Exist
#3
Corporate Philosophy — Putting Trust into Words
#4
Policies — From Principle to Direction
#5
SOPs — From Policy to Procedure
#6
Ethics and Norms — The Undocumented Territory
Advertising Regulation
8 chapters
Advertising Reg.
#1
Ad Regulations 01 — Pharmaceutical Act §§66–68 and the Two Cases That Shaped the Industry Norms
#2
Ad Regulations 02 — The Suspecting Eye: Reading Risk Beyond Regulation
#3
Pharmaceutical Product Advertising Appropriateness Standards — Operationalizing PAA Article 66
#4
MSA Guidelines — Drawing the Line for MR Information Provision
Part 1. Basic concept
+3
1. Purpose
2. Scope of application
3. Principles of MSA activities
+3
Principle (1) Requirements to satisfy
Principle (2) Prohibited acts
Principle (3) Acts to perform proactively
Part 2. Duties of manufacturers/distributors
+9
1. Duties of management
2. Internal structure
3. Ensuring appropriateness of materials
4. Evaluation and education
5. Monitoring and supervision
6. Procedures and records
7. Responding to improper activities
8. Complaint handling
9. Contractors, partners, wholesalers
Part 3. Duties of activity staff
+4
1. Compliance with the Guidelines
2. Points of attention during activities
3. Self-improvement
4. Ban on using improper materials
Part 4. Other matters
+8
1. Matters not explicitly stated
2. Response by related associations
3. Information on unapproved/off-label drugs
4. Compliance with other laws
5. Exception for contractors/partners
6. Exception for wholesalers
7. Duties of healthcare professionals
8. Date of application
#5
MSA Q&A Compendia — When MHLW Answers Field "Which Way?" Questions
Q&A Part 1
+39
▸ Part top (commentary & cases)
Q1 Is information provision under GCP/GPSP/GVP outside the scope?
Q2 Does 'expecting sales promotion' equal customer inducement?
Q3 Is pre-approval communication by clinical development teams exempt?
Q4 Can internal rules separating MA/MSL from sales avoid the Guidelines?
Q5 Is disease awareness activity under proper advertising standards exempt?
Q6 Is information provision to contracted healthcare professionals exempt?
Q7 Are external expert lectures at company-sponsored events covered?
Q8 Does the Guideline apply to non-sales employees' activities?
Q9 Can review reports justify off-label information provision?
Q10 Does the approved-scope limit apply only to own products?
Q11 May off-label adverse event data be shared as safety alerts?
Q12 Is balanced provision including unfavorable information required?
Q13 Must peer-reviewed articles also allow objective evaluation and verification?
Q14 May pre-Clinical Trials Act external studies be cited in materials?
Q15 May non-Japanese external studies outside the Clinical Trials Act be cited?
Q16 Is best-effort confirmation of ethical guideline compliance sufficient?
Q17 If a paper lacks a COI disclosure, can companies record only what they know?
Q18 What specific negative information must be provided?
Q19 Can review and monitoring be handled by separate organizational units?
Q20 Can sales staff serve as monitoring practitioners in the supervisory department?
Q21 Can the Medical Affairs department serve as the supervisory department?
Q22 Can the supervisory department be composed of multiple existing departments?
Q23 Can the review and supervisory committee be placed outside the supervisory department?
Q24 What degree of independence is required for a person "independent from the company"?
Q25 Can an external expert who reviews materials also serve as the independent member of the committee?
Q26 Does a person in a global organization outside the Japanese president's authority qualify as independent?
Q27 Can the review and supervisory committee's functions be outsourced to an external body?
Q28 What does it mean in practice for management to reflect promotional conduct in employee evaluations?
Q29 Is there a recommended frequency for monitoring and committee reporting?
Q30 Are there mandatory items that must be covered in the SOPs?
Q31 Is a simplified record sufficient for verbal explanations during visits?
Q32 Is there a recommended retention period for business records?
Q33 Is there a prescribed method for publicizing the complaints contact externally?
Q34 Can existing customer inquiry channels be repurposed as the complaints contact?
Q35 Can MRs provide information on unapproved or off-label drugs?
Q36 Is there a recommended retention period for records on unapproved/off-label drug information?
Q37 Do the Guidelines apply to media seminars and press releases?
Q38 What bodies are covered by the term "related associations"?
Q&A Part 2
+28
▸ Part top (commentary & cases)
Q1 Scope of off-label/unapproved drug information that may be provided on request
Q2 Scope of information on overseas indications/dosages not approved domestically
Q3 Providing information on indications/dosages whose approval was revoked after re-evaluation
Q4 Scope of clinical trial data that may be provided for unapproved/off-label drugs
Q5 Providing information on pediatric use not explicitly described in the package insert
Q6 Scope of development status information (clinical trial information) for unapproved drugs and new indications
Q7 Providing unapproved quality information such as single-dose packaging stability and compatibility
Q8 Providing information on simple suspension method not covered by approval
Q9 Whether pre-prepared response documents for frequently requested off-label information are permissible
Q10 Whether a treatment guideline containing off-label information may be provided
Q11 Whether published post-marketing surveillance results containing unapproved dosage information may be provided
Q12 Whether a peer-reviewed original article containing off-label information may be provided
Q13 Whether companies may proactively provide off-label information based on a healthcare professional's known area of interest
Q14 Whether information provided to one requesting physician may be distributed to other non-requesting physicians or pharmacists
Q15 Whether off-label information may be proactively provided to physicians with prior use experience
Q16 Responding to requests during in-person discussions with healthcare professionals
Q17 Use of unapproved drug data in internal development meetings attended by contracted physicians
Q18 Providing unapproved drug information to healthcare professionals for co-authoring academic articles
Q19 Precautions when providing off-label information orally by telephone at a medical information center
Q20 Providing information to additional healthcare professionals who join an ongoing session
Q21 Whether to answer an off-label question publicly in a multi-physician departmental briefing
Q22 Whether information may be provided to another staff member when the requesting physician or pharmacist is absent
Q23 Responding to requests for off-label information at an academic conference exhibition booth
Q24 Whether attendance at an overseas affiliate's lecture constitutes information provision by the Japanese parent company
Q25 Whether Medical Affairs employees may present trial data at academic conferences
Q26 Providing information on indications approved only for the originator drug but not the generic (gap indications)
Q27 Scope of clinical trial information that may be provided to patient organizations upon request
Q&A Part 3
+2
▸ Part top (commentary & cases)
Q1 May stability data for simple suspension/crushing be included in the Interview Form for provision?
Q&A Part 4
+15
▸ Part top (commentary & cases)
Q1 Can information on competing products or comparative data be provided when requested by physicians or pharmacists?
Q2 Can comparative information drawn from package inserts, IFs, or treatment guidelines be provided?
Q3 Can comparative efficacy information be provided when requested?
Q4 Can efficacy comparative data from conference presentations not yet published as papers be provided?
Q5 Can a comparative efficacy table be provided when specifically requested?
Q6 Can comparative safety (adverse event) information be provided when requested?
Q7 Can comparative data on contraindications, precautions, interactions, or specific adverse events be provided when requested?
Q8 Can switching dose information from a competing product to one's own, drawn from unpublished conference data, be provided?
Q9 Can comparative drug pricing information be provided when requested?
Q10 Is comparative information completely prohibited when no request is made by physicians or pharmacists?
Q11 Can off-label use information be provided on the spot when requested in real time?
Q12 Can the latest conference presentation data also be provided as off-label use information?
Q13 Can a treatment guideline containing information on domestically unapproved drugs be provided when requested?
Q14 Can information confirming that off-label use is listed on public government/insurer websites be provided?
#6
JPMA Code of Practice — A Voluntary Industry Norm Above the Law
#7
JPMA Material-Creation Guide (the "Toranomaki") — A Practical Manual for Producing Materials
#8
Advertising Regulation ── Promotional Activity Monitoring Project: ten years of incidents
Foundations — the foreword's spirit and the discipline of science
I. Product Information Summary
+3
Ch.1 Basic considerations
Ch.2 Comprehensive product information summary
+16
(1) Cover items
(2) Development history
(3) Features (characteristics)
(4) Product information (DI)
(5) Clinical results
(6) Pharmacokinetics
(7) Pharmacology
(8) Safety pharmacology & toxicity
(9) Physicochemical findings
(10) Formulation matters
(11) Handling precautions
(12) Packaging
(13) Related information
(14) Key references
(15) Marketing-authorization holder
(16) Date of preparation or revision
Ch.3 Specific-item product information summary
II. Specialist-journal (print) advertising
+3
Ch.1 Standard advertising
Ch.2 Product-name advertising
Ch.3 Editorial-style advertising
III. Other materials
+11
Ch.1 Presentation content
Ch.2 Lecture/seminar proceedings
Ch.3 Conference posters and panels
Ch.4 Notices (to institutions)
Ch.5 Disease-explanation materials
Ch.6 Patient-facing materials
Ch.7 Product lists
Ch.8 Compatibility tables
Ch.9 Conference abstracts/proceedings
Ch.10 Article reprints
Ch.11 Abstract collections
Materials
Material Review Essence
Domestic 10 + Overseas 3
Domestic Series (10 Eps)
L1
Getting to the Essence of Promotional Material Review
L2
Building the Regulatory Pyramid in Your Head — All must be upheld; what differs is the risk of breach
L3
Material Review Vol. 3 — Efficacy and Effect Within the Approved Scope
L4
Former Colleagues — Relationship with Marketing
L5
Supervisor Conflicts of Interest — Sales vs. Trust
L6
Called "the Naysayer" — Structure of Psychological Load
L7
Train Driver and Material Review — "Nothing Happens" as Success
L8
Buried Outcomes — The Cost of Going Unrecognized
L9
Solo-Defender Structure — Stop Alone, Be Blamed Alone
L10
Fear of Missed Findings — Nights of "I Could Have Stopped It"
Overseas Series
Overseas 01
The International Lens 01 — United States: Inside FDA OPDP
Overseas 02
The International Lens 02 — Europe: EFPIA and the Layered National Regulations
Overseas 03
The International Lens 03 — Asia-Pacific + Japan in Parallel
Production Quality Mgmt
10 Episodes
Production QM
L1
Chapter Purpose and Scope
L2
Lifecycle Design for Vendor Engagements
L3
Regulatory Map — PMD Act §66–68, Standards, MSA Guideline, JPMA
L4
Building Quality Checks That Leave No "Reasonable Doubt"
L5
AI Prompt Library — Detecting Regulatory Violations
L6
Running AI Checks and Handling the Results
L7
QC SOP (Standard Operating Procedure)
L8
QA SOP (Quality Assurance SOP)
L9
Per-Medium Check Sheet Templates
L10
Signed Delivery and Traceability
Content Owner Responsibility
10 Episodes
Owner Responsibilities
L1
Chapter Purpose and Scope
L2
The Structure of Moral Responsibility — Why "Pass-through" Fails
L3
End-to-End Receiving Workflow
L4
SoW (Statement of Work) Consistency Check
L5
Reading Vendor QC/QA Records
L6
Independent Re-Check — Catching Vendor Misses and Over-flags
L7
JPMA Standards Alignment — Per-Medium Check
L8
Internal Code of Practice / Policy / SOP Consistency
L9
Mid-Gate Decision Criteria — Submit / Return / Hold
L10
Documenting and Archiving Moral Responsibility
Reviewer Development
3 series × 10 parts
Introduction — Get the Map First
The Eight Abilities a Reviewer Needs
Vol. 1
The Essential Question ── Who Detects, Pushes Back, and Embeds the Gap
Vol. 2
Seeing People on Two Axes ── Quadrant, and Scale/Level/Divergence
Vol. 3
Knowledge ── Not Volume but the Density of the Connective Web
Vol. 4
Intelligence ── Seeing Through Form to Judge by Substance
Vol. 5
Risk Detection ── Reading What Is Not Written
Vol. 6
Intuition ── The Alarm That Precedes Words
Vol. 7
Communication ── A Correctness That Doesn't Land Doesn't Exist
Vol. 8
Behavior-Change Inducement ── Intrinsic, Even When Unwatched
Vol. 9
Relationship Building ── Neither Enemy Nor Ally, a Trusted Third Party
Vol. 10
Trust Density ── The Medium That Makes It Work, and the Whole
The Anatomy of Failure
01
Promotion of Unapproved or Off-Label Indications and Dosage
02
Claims Lacking Evidence or Scientific Basis
03
Cherry-Picking, Data Manipulation, and Selective Presentation
04
Exaggerated and Misleading Expressions
05
Emphasizing Efficacy While Downplaying Safety
06
Disparagement and Defamation of Competitors' Products
07
Undisclosed Conflicts of Interest and Improper Conduct in Lectures and Prescribing Guidance
08
Cross-Category Violations Rooted in Process Failures
The Compound Eye of Review
01
Two Ways of Seeing — Why Reviewers Need Both the Rule-Eye and the Recipient-Eye
02
Micro-Level Reading — Knowing the Rules, and Why They Exist
03
Perspective-Taking as Method — Making Knowledge Personal
04
The Patient's Eye — I Am the One Who Takes This Drug
05
The Family's Eye — Spouse, Parent, Adult Child at the Bedside
06
The Lawyer's Eye — Can This Material Survive Cross-Examination?
07
The Regulator's Eye — Reading Your Own Materials from the Inspection Standpoint
08
Media & Public Scrutiny — Imagining the Front-Page Headline
09
Integrating Lenses — Switching, Holding, and Merging Perspectives
10
Making the bird's-eye view a habit — reading past failures as a mirror
Developing Material Creators
Overview + 29 chapters
Overview ── The Whole Picture
Learning from Past Incidents
01
Data Misuse and Manipulation That Risk Factual Misrepresentation
02
Selective Data Extraction, Manipulation, and Presentation
03
Claims Without Evidence / Unreliable Data
04
Presenting Unapproved Indications and Dosage Regimens
05
Exaggerated Claims
06
Efficacy-Only Promotion / Safety Information Neglect
07
Disparagement of Competing Products
08
COI Non-Disclosure
09
Other Improper Sales Practices
Inside the Creator ── The Psychology Behind Deviations
01
A Map of Pressure — How Good Intentions Bend
02
The Creed Trap — "I Want to Help Patients" as the Entry Point
03
Conclusion First, Data Second — Motivated Reasoning
04
"Just One Slide" — Local Rationalization
05
The Choice Not to Speak — The Sin of Omission
06
Structures That Let You Blame Someone Else — Externalizing Responsibility
07
The Gravity of Numbers — Quotas and the Psychology of Incentives
08
The Anxiety of Competition — How Panic Becomes Disparagement
09
The Silent Organization — Conformity Pressure, Hollow Audits, and the Self That Won't Disclose
10
Redesigning Pressure — Individual Psychology and Organizational Systems
As We Should Be ── Ten Convictions for Material Creators
01
Scientific Evidence Steward — I Am Not a Salesperson
02
Taking Responsibility for the Reader's Mental Image
03
The Conscience That Doubts Conclusions — Led by Data
04
Sign the Whole — Not Just One Slide
05
Duty to Tell — Efficacy and Safety on Equal Footing
06
Own It — Don't Hide Behind "The Physician Decides"
07
The Right Distance from Numbers — Quotas as Constraints, Not Goals
08
Respect for Competitors — Fair Play Builds Trust
09
Staying Open — Disclosing Limitations, Uncertainty, and Conflicts of Interest on Your Own
10
Embedding Conscience into the Organization's Systems — From the Individual to the Organization, Made Visible
Perspectives
The Four Layers of Management
The management view in five layers · 5 Series × 10 ·
Ⅰ The Capitalist's View
#1
Who Is the Capitalist? — Mapping Shareholders, Founders, Institutional Investors, and Private Equity
#2
Why Profit Is Required — The Invisible Rent Called the Cost of Capital
#3
Before You Commit a Single Yen — NPV, ROIC, and the Hurdle Rate
#4
Risk Gets a Price — How Return and Diversification Relate
#5
The Separation of Ownership and Control — The Origin of the Agency Problem
#6
What Shareholders Can and Cannot Do — Voting Rights, Dividends, and Residual Assets
#7
The Quarter and the Decade — Short-Termism vs. Long-Term Value
#8
Capital Allocation — Dividends, Buybacks, Reinvestment, and M&A
#9
The Price of Misconduct — When a Breach of Norms Is Priced Into the Cost of Capital
#10
Materials Review Through the Capitalist's Eyes — Trust as an Intangible Asset
Ⅱ The Board's View
#1
The Board Does Not Manage — Separating Supervision from Execution
#2
Fiduciary Duty — How the Duty of Care Differs from the Duty of Loyalty
#3
How to Read a Governance Code — The Discipline of "Comply or Explain"
#4
Why Outside Eyes Are Needed — The Independence of Outside Directors
#5
The Three Committees — Why Separate Nomination, Compensation, and Audit
#6
The Duty to Build Internal Controls — What Article 362(5) of the Companies Act Imposes
#7
Setting Risk Appetite — How Much to Take Is Approved by the Board
#8
The Three Lines of Defense — Dividing Roles Among the Front Line, the Management Function, and Internal Audit
#9
Why "I Didn't Know" Doesn't Hold — How Far the Duty to Monitor Reaches
#10
Materials Review Seen from the Boardroom — The Visible Evidence That Governance Is Working
Ⅲ The Executives' View
#1
What Is the Executive Team? — Dividing Roles Among the CEO, CxOs, and Executive Officers
#2
Turning Strategy into Execution — The Dynamics of KPIs and Resource Allocation
#3
Top-Line Pressure — Why Sales Leans Forward
#4
The Three Pillars of Management — How Strategy, Organization, and Finance Mesh
#5
People Act Through Systems — Designing Evaluation, Reward, and Incentives
#6
The Traps of Executive Judgment — Confirmation Bias and Sunk Cost
#7
Revenue and Compliance — Trade-off, or Integration?
#8
Execution After a Scandal — First Response, Disclosure, and Recurrence Prevention
#9
Executives and the Review Function — The Structure of Friction and Collaboration
#10
Material Review from the Executive's Eyes — Steering Wheel, Not Brake
Ⅳ Management and Risk
#1
Defining Risk — Uncertainty and Exposure
#2
Why Do Firms Take Risk? — The Source of Returns
#3
Risk Appetite and Tolerance — The Line the Board Draws
#4
The Big Picture of ERM — COSO and ISO 31000
#5
The Three Lines of Defense Revisited — Separation of Roles and Independence
#6
Measurable and Unmeasurable Risk — VaR and Tail Risk
#7
The Singularity of Compliance Risk — Low Frequency, High Severity, Reputational Damage
#8
The Risk That Incentives Create — Compensation Design and Runaway Behavior
#9
The Chain of Crisis — How a Deviation Spreads to Governance and Capital
#10
Materials Review Seen Through Risk Management — Ex Ante Risk Reduction and the Node of the Three Layers
Metacognition
Introspection · 3 Series × 10 Episodes
Self-Understanding
第1回
Look into the Mirror — What Jung, Freud, and Adler Left Us
第2回
The Gap Between Self-Perception and Others' Perception — The Looking-Glass Self and Johari Window
第3回
Quietly Acknowledging the Self That Falls Short — Rogers, Confucius, Brown
第4回
Anger Is a Mirror of the Heart — Aristotle, Mencius, Buddhism, Adler
第5回
The Meaning of Insisting on Good and Bad — Nietzsche, Zen, Laozi, Confucianism, Berlin
第6回
Jung's Type Theory — Introversion, Extraversion, and Mapping Your Habits
第7回
The True Face of Irritation — A Story of Repressed Desires
第8回
What Am I? — Zhuangzi's Butterfly Dream and Cartesian Doubt, 2300 Years of the Question
第9回
Jealousy and Envy — Ressentiment and "Worry Not That Others Know You"
第10回
Polishing the Mirror — Nine Paths of Self-Understanding, One Practice
Overconfidence
第1回
The Greatest Trap of Overconfidence — Moments of Losing the Self
第2回
The Blind Spot of Metacognition — Dunning-Kruger and the Structure of Not Knowing What One Does Not Know
第3回
Freud's self-regulation and defense mechanisms ── Unconscious structures that support overconfidence
第4回
The psychology of blaming outsiders ─ The relationship between self-serving attribution bias and overconfidence
第5回
Reading the signs of overconfidence ── Techniques for observing overconfidence in yourself and others
第6回
Why you can't learn from failure - Overconfidence hinders learning
第7回
Between overconfidence and humility --- The question of moderation that separates confidence from overconfidence
第8回
Practices to reduce overconfidence ── Calibration training and the pre-mortem
第9回
Between the ideal self and the real self ── Overconfidence caused by a discrepancy between Jungian self-images
第10回
Living with overconfidence ─ Etiquette of coexistence and monitoring rather than complete erasure
Self-Affirmation & Self-Criticism
第1回
The Trap in the Word "Self-Esteem" — The Limits of Positive Psychology
第2回
The Structure of Self-Criticism — From Freud's Superego to Brené Brown's Shame Research
第3回
Healthy vs. Pathological Self-Criticism — Where to Draw the Line
第4回
Three Misunderstandings of Self-Affirmation
第5回
The Buddhist Middle Way — A Third Path Beyond Affirmation and Criticism
第6回
Adler's "Separation of Tasks" — Detaching the Self from Others' Evaluations
第7回
Stoics and Modern Self-Acceptance (Coming Soon)
第8回
Calibration — Practices for Improving the Accuracy of Self-Evaluation (Coming Soon)
第9回
Reflecting on Failure — Bridging from Self-Criticism to "the Next Action" (Coming Soon)
第10回
The Endpoint of Metacognition — The "Observer Self" (Coming Soon)
Self-Transformation
Transformation · 2 Series × 10 Episodes
Self-Transformation
第1回
Self-Transformation Is Not Self-Negation — The Practice of Change That Begins with Acceptance
第2回
Rewriting the Past — The Fact Cannot Be Changed, but the Meaning Can Be Rewritten by Today's Judgement
第3回
Decisively Broken Relationships and the Meaning of Reconciliation — For Oneself, Not for the Other
第4回
Self-Transformation and Self-Acceptance Are Two Wheels — Because You Accept, You Can Change
第5回
A Science of Failure — Turning Emotional Events into Data for Learning
第6回
The Practice of Those Who Keep Changing — Living with a Self That Never Reaches Completion
第7回
Habit as Second Nature — Heksis and "The Highest Good Is Like Water"
第8回
The Art of Forgiving Yourself — Kierkegaard, Compassion, and Reconciliation with Failure
第9回
The Practice of Courage — Adler Revisited
第10回
The "End" of Transformation Is the "Beginning" — Through Nine Chapters, Into Tomorrow
Confidence
第1回
What Is Confidence? — The Three Views Left by Jung, Freud, and Adler
第2回
When Confidence Collapses — The Anatomy of Anxiety, Shame, and Inferiority
第3回
Between Interior and Exterior — Which Comes First, Inner Confidence or Outer Bearing?
第4回
The Voice as a Mirror of Confidence — Tone, Pace, and the Power of Pauses
第5回
The Science of Facial Expression — From Ekman's Basic Emotions to Microexpressions
第6回
Creating Atmosphere — The Practice of Bearing, Gesture, and Space
第7回
The Dynamics of Gaze — What the Eyes Convey and Conceal
第8回
The Science of Confidence — Self-Efficacy and Cognitive-Behavioural Research
第9回
Confidence as Negotiating Advantage — Position, Ethics, and Parity
第10回
The Practice of Lasting Confidence — Daily Habit and the Cycle of Reflection
Communication
Dialogue · 10 Episodes
Communication
第1回
Is There Any Point in Pursuing Correctness? — Beyond Correctness, Toward Reaching
第2回
The Blade Called Justice — Is My Justice Wounding Someone?
第3回
"Correct" and "Reaching" Are Different Things — Designing Context, Timing, and Temperature
第4回
The Trap of Confirmation Bias and Negative Marking — Putting One's Own Cognitive Habits on the Design Table
第5回
The Curse of the Expert — The Very Knowing Makes Transmission Hard
第6回
The Zero-Risk Illusion and Over-Finding — An Adult Relationship with Risk
第7回
Active Listening — "Listening" Changes Judgement
第8回
Turning Feedback into Words That Reach — A Design That Turns Comment into Growth
第9回
The Skill of Dialogue with Those Who Hold Opposing Views — Beyond Conformity Pressure
第10回
The Ethics of Communication — Silence as a Choice
The Justice Disease
Vol. 1
Onset ── The Pleasure of Being Right
Vol. 2
The Proximity Trap ── When the Rule Becomes the Whole World
Vol. 3
Black or White ── The Disappearance of Gray
Vol. 4
Amplification ── When Subjectivity Becomes Justice
Vol. 5
The Fault-Finder ── Everyone Looks Like the Enemy
Vol. 6
Metacognitive Failure ── Unable to See Oneself
Vol. 7
Complications ── The Harm of Over-Correction
Vol. 8
Turning Point ── The Day I Saw Gray
Vol. 9
Remission ── Reclaiming Context
Vol. 10
Coexistence ── Living with Justice Disease
The Justice Disease II
Vol. 1
Promotion ── From Judge to Bearer
Vol. 2
The Weight of the Whole ── Stopping Was Never Enough
Vol. 3
The Logic of Numbers ── P&L as a New Language
Vol. 4
The Loneliness of Trade-offs ── Decisions That Resist Black and White
Vol. 5
A Subordinate's Justice Disease ── Seeing a Former Self
Vol. 6
The New Justice Disease ── The Trap of Managerial Orthodoxy
Vol. 7
Power and Metacognition ── No One Will Stop You Now
Vol. 8
What Are We Protecting? ── The Purpose Behind Rules, Revisited
Vol. 9
Bridging ── Becoming the Translator Between Two Worlds
Vol. 10
Every Day a Good Day ── Self-Monitoring Without End
The Justice Disease III
Vol. 1
Taking the Seat ── The View from Governance
Vol. 2
Rules Are an Effect ── The Culture Downstream of Norms
Vol. 3
The Wiring Diagram ── Incentives Decide Behavior
Vol. 4
The Boardroom's Blind Spot
Vol. 5
The Valley Between the Stated and the Real
Vol. 6
Beyond Hunting for Violations ── Designing the Conditions in Which Judgment Grows
Vol. 7
The Whistle as a Mirror
Vol. 8
Organizational Metacognition ── When a Company Sees Itself
Vol. 9
My Former Self, Now Visible
Vol. 10
The Governor's Every Day a Good Day
AI
AI Literacy
10 series × 10 episodes · daily
AI Literacy — contents
S1
Sparks and Conception
S2
Ideal versus As-Is
S3
Putting It into Words
S4
From a Rough Wish to a Request
S5
Concept
S6
Making It Logical
S7
Blueprints
S8
Programs
S9
Running It
S10
AI Literacy
AI Foundations
Intro · 4 Episodes
AI Foundations
L1
Foundations — AI Terms & Concepts
L2
AI Lectures Vol. 2 — Build Source-Consistent Documents with AI (Phrase Structure Grammar, 10 Hands-On Steps)
L3
Email, Minutes, Summaries — 30 Minutes a Day with AI
L4
Documents and Diagrams — AI for Becoming Someone Who Can Explain
AI Applied Series
Practice · 5 Series × 10 Episodes
AI Marketing
L1
Marketing Redefined for the AI Era: "Advertising → CRM → Content → Brand"
L2
AI Agent for Marketing “The era of delivering to agents rather than people”
L3
Vibe Marketing “Designing the “Atmosphere” of a Brand”
L4
New dimension of personalization “From 1to1 to 1to-Self”
L5
AI-Generated Content Strategy: Building Review Into a 'Fast to Make' Era
L6
Predictive Marketing: Anticipating "What You Want Next"
L7
Virtual Influencer Ethics: The Boundaries of an AI-Made "Persona"
L8
CRM × AI: Putting AI Into Customer Relationship Management
L9
Automated Creative Optimization: Infinite Generation and Automated A/B
L10
The World After Cookies: Marketing Without Tracking
AI Programming
L1
The Foundations of Code Generation: What an LLM Can and Cannot Write
L2
Working With Copilot: The Practical Discipline of Completion-Type AI
L3
Prompt Engineering: Designing Instructions That Reproduce
L4
Writing Tests With AI: Between Generation and TDD
L5
Refactoring: Safe Improvement with AI Assistance
L6
Generating Documentation: The Limits of Turning Code into Prose
L7
AI Security and Vulnerabilities: The Risks of Generated Code
L8
Model Selection and Cost Optimization: Choosing the Right Tool for the Task
L9
Architecture Design: How to Use AI as a Design Advisor
L10
AI Pair Programming: How People and AI Work Together
AI Medical
L1
Medical AI Today: The Whole Picture, and Separating Out the Overstatement
L2
Clinical Decision Support (CDSS): It Assists, It Does Not Replace
L3
Diagnostic Imaging AI: The Real Power and the Pitfalls of Reading Support
L4
EHRs and AI: Recording, Summarizing, Voice Input
L5
Drug-Discovery AI: From Target to Clinic
L6
PMDA and AI Medical Devices: The Practice of Approval and Regulation
L7
The Ethics of Medical AI: Fairness, Explainability, Consent
L8
The Physician's AI Literacy: The Power of the One Who Uses the Tool
L9
The AI Strategy of a Pharmaceutical Company: From R&D to Commercial
L10
The Future of Medical AI: A 5-to-10-Year Outlook and Its Principles
AI and the Economy
L1
AI as a General-Purpose Technology — What the Productivity J-Curve Reveals
L2
AI and Productivity — From +14% to −19%, What the Studies Actually Show
L3
AI and Jobs — 80% of Workers Have Tasks Exposed
L4
The Cost Structure of AI — Training at $78 M, Inference Down 280×
L5
The AI Investment Wave — $700 Billion a Year Flowing into Data Centers and Power
L6
AI and Market Concentration — FTC, CMA and JFTC Raise Three Competition Risks
L7
AI and International Competition — CHIPS Act, Export Controls and the EU AI Act
L8
AI and Health Economics — Can the $2.2 Billion-Per-Drug Model Change?
L9
AI and the Pharma Business Model
L10
Distributing the AI Economy and the 1.6-Point Drop in Labour Share
AI and Finance
L1
AI in Finance Today — FSB Report and the 75% Adoption Rate
L2
AI and Capital Markets
L3
AI Capex at $725 Billion and the Distance to Revenue
L4
The Quarter AI Took 80% of Venture Capital
L5
Three Regulatory Frameworks for AI in Finance: Japan, the EU and the US
L6
Why SR 26-2 Excluded Generative AI
L7
PCAOB and IAASB Question AI Audit Accountability
L8
$20 Billion into AI Drug Discovery, Zero FDA Approvals
L9
DORA's 19 Designated Providers and AI Concentration Risk
L10
BIS and FSB Chart the Course for AI Financial Regulation
AI and Emerging Technology
Essays · Weekly
AI and Emerging Technology — last 10
09/19
A peer-reviewed perspective published in Cell examines three agentic AI systems — Co-Scie…
09/19
A peer-reviewed perspective in NEJM AI proposes a phase-based framework for evidence stan…
09/19
SoL-Pi, a preprint from NVlabs and collaborators, reports halving token consumption for c…
09/18
LimiX-2, a new foundation model for structured data, replaces the conventional 'predict y…
09/18
Game AI used to mean beating humans at chess or Go
09/17
Published in Nature Medicine, CRISP is a foundation model for intraoperative pathology bu…
09/17
How can an AI agent continuously improve its own exploration strategy? Dream-RSI proposes…
09/17
PhysBrain 1.5 unifies environment understanding, action generation, and future state pred…
09/13
The U.S. Department of Energy is developing open-weight AI models purpose-built for scien…
09/12
Marigold V2 converts a diffusion transformer trained for image generation into a single-s…
AI Daily News
Daily digest · last 10
AI Daily News — last 10 issues
09/19 PM
An unprecedented security incident occurred in which Google's Gemini AI actually "infiltrated" the corporate…
09/19 AM
Multiple media outlets reported the news that Anthropic's Claude was used by a security researcher for "ethic…
09/18
While OpenAI announced its law-specific model "Astra for Law," it also announced six cases of rogue behavior…
09/17
Controversy over AI safety has become a central theme in the industry
09/16
Multiple media outlets have reported that OpenAI, Anthropic, and Google have entered into discussions to buil…
09/15
The biggest focus is on the ``AI pacing'' controversy
09/14
AI industry news for 2026-09-14
09/13
The biggest news of the past 12 hours was an unprecedented development in which industry leaders such as Sam…
09/12
The biggest topic of discussion was the threat report published by Anthropic, which detailed examples of Clau…
09/11
Anthropic announced that it had detected and blocked the misuse of Claude for biological weapons development,…
AI Daily Update Video
One a day · 15 min
AI Daily Update Video — latest edition
09/19
The day AI hacked itself 10:52
09/18
The day a maker disclosed its own faults 10:51
09/17
The day AI firms began attacking each other 10:52
09/16
The day three rivals joined hands on safety 10:30
09/15
The day the slowdown argument entered politics 11:05
09/14
The Day an AI Developer Admitted the Lie 11:24
09/13
The Day Caution Got a Price Tag 11:38
09/12
The Day AI Leaders Talked About Slowing Down 9:47
AI and the Pharmaceutical Industry
Pharma × AI capital · Daily · last 10
AI and the Pharmaceutical Industry — last 10 issues
09/19
Pharma-AI investment coverage on September 19, 2026 was dominated by capital concentrating in drug discovery
09/18
Today's biggest focus is the Novo Nordisk–Anthropic partnership
09/17
Today's focus is on ByteDance's AI drug discovery subsidiary Anew Labs raising $290 million at a $1.5 billion…
09/16
Today's notable development was the OpenAI Foundation's funding commitment to an AI healthcare program built…
09/15
$13.3 Mn — Graph AI Secures $13.3 Mn Series A To Scale AI Drug Safety Platform
09/14
AI and the Pharmaceutical Industry — 2026-09-14
09/13
Pharma×AI investment coverage for 2026-09-13 features a single item: Fundly.ai raised $4.9 million to expand…
09/12
Today's pharma-AI coverage was limited to three items, only one of which involved a disclosed dollar figure
09/11
Pharma-AI coverage on September 11, 2026 was thin, with only two items reported
09/10
$400B — Major Pharma News July–August 2026 | $400B Merger, AI, GLP-1s & India Pharma Updates Ben Stiller (oud…
AI Economy & Finance
Daily digest · last 10
AI & Economy — last 10
09/19 PM
Musk claimed that AI could double US GDP growth to 4% next year, and UBS predicted that AI capital investment…
09/19 AM
With the expansion of AI-related capital investment and the tightening of electricity infrastructure, capital…
09/18
While AI-related capital investment supports economic growth, there are growing concerns that the scale of in…
09/17
While AI capital investment continues to expand, skepticism about productivity improvements and alarmism abou…
09/16
ECB President Christine Lagarde appealed for Europe's strategic autonomy, saying, ``It is not enough for Euro…
09/15
The past 12 hours have seen the market dominated by skepticism about the sustainability of AI capital investm…
09/14
The wages of American workers are under pressure. AI's potential role is drawing more attention
09/13
At the same time, Christine Lagarde cited the €630 billion economic boost from AI, while Anthropic's founder…
09/12
AI-related hardware stocks have soared on the back of Oracle's $95B capital investment plan, and an overheate…
AI & Finance — last 10
09/19 PM
Meanwhile, capital continues to flow into AI infrastructure, including Nvidia's $2b investment in the Brookfi…
09/19 AM
Implementation of financial agent-type AI (agentic AI) is progressing simultaneously in banking, payment, and…
09/18
Mastercard and Visa successively announced platforms that enable autonomous payment and purchasing by AI agen…
09/17
Big debt funding for AI data centers grows as banks lend $22 billion to Blackstone and Alphabet's AI joint ve…
09/16
The actual implementation of AI agents by banks and asset management companies is accelerating, and major com…
09/15
Wall Street's investment decisions and AI leaders' warnings are mixed regarding the sharp decline in AI stock…
09/14
Goldman Sachs Says AI Is Driving Half of S&P 500 Earnings Growth. That Number Cuts Both Ways
09/13
The biggest move is that NVIDIA is considering investing $10B in Anthropic's IPO (valuation $2.3T) (Reuters,…
09/12
JPMorgan's suspension of lending to AI hedge funds due to losses from AI trading stands out as a move emblema…
Microsoft Copilot Know-how
Microsoft 365 · 10 apps + 6 topics · sourced
Microsoft Copilot Know-how — index
01
Word ── Draft, summarize, rewrite
02
Excel ── Analysis, formulas, charts
03
PowerPoint ── Slides from documents, summaries
04
Outlook ── Summaries, replies, scheduling
05
Teams ── Meeting and chat recaps
06
OneNote ── Note summaries, to-dos
07
Loop ── What remains, what to use instead
08
SharePoint / OneDrive ── Summarize and compare files
09
Copilot Chat ── Work IQ, Researcher, saved prompts
10
Notebooks / Pages ── Gather references and ask
11
Choosing Between Opus and GPT ── Choosing a model
12
Building AI Agents with Agent Builder ── Build with Agent Builder
13
Operating AI Agents ── Admin, billing, audit
14
Working with OneDrive ── Storage and file references
15
Grounding Copilot in Your Stored Content ── Permissions, labels, oversharing
16
Concept Search and Insight across OneDrive Documents ── Search by meaning, check understanding
Microsoft Copilot Advanced
Apps × Python · 16 pages
Microsoft Copilot Advanced — index
A01
Excel × Python ── Python in Excel, pandas, openpyxl
A02
Word × Python ── Extract and check with python-docx
A03
PowerPoint × Python ── Batch checks with python-pptx
A04
Outlook × Python ── Tally mail and events via Graph
A05
Teams × Python ── Notifications, messages, bots
A06
SharePoint / OneDrive × Python ── Drives, lists, delta queries
A07
Document Search × Python ── BM25, embeddings, hybrid search
A08
Agents × Python ── Adding Python to agents
A09
Code Execution in Copilot ── Code execution and checking
A10
Power Automate × Python ── Flows with Python
A11
End-to-End Manual ── End to end, one worked example
A12
Computational Thinking ── Decompose, abstract, verify
A13
From Instructions to Code ── Prompt patterns for code
A14
Choosing Where Code Runs ── Choosing a runtime
A15
Authentication, Permissions and Governance ── Auth, least privilege, audit
A16
Workflow Recipes ── Document workflow recipes
Column
AI Review
Algorithm Guide
Design & implementation · 4 pages
AI Review Algorithm
00
Hub — The whole picture of AI review
01
Design Philosophy — What the system protects
02
Components — The structures behind it
AI Material Review Series
Practice · 10 episodes
AI Material Review
Vol. 1
AI and Material Review — What's Happening Now
Vol. 2
How to Review AI-Generated Materials
Vol. 3
Detecting Deviations with AI
Vol. 4
Giving AI the Rules — Guardrail Design
Vol. 5
Standardizing Review with AI
Vol. 6
The Power and Limits of AI Review Tools
Vol. 7
Review Records and Audit Trails with AI
Vol. 8
Reviewers' AI Literacy
Vol. 9
Review Governance in the AI Era
Vol. 10
The Future of AI Material Review
Sitemap
Updates
Disclaimer
Home
/
AI Daily News
/ Monthly
AI Daily News Monthly Aggregate — Archive
Monthly
Monthly meta-analysis covering the past 30 days. Cross-period synthesis of major AI labs, regulators, and notable figures.
2026-08
Monthly
Monthly meta-analysis covering the past 30 days. Cross-period synthesis of major AI labs, regulators, and notable figure...
2026-07
Monthly
Monthly meta-analysis covering the past 30 days. Cross-period synthesis of major AI labs, regulators, and notable figure...
← AI Daily News Index